Here’s what I gathered from the video: 1. The
Post# of 154119
(Total Views: 503)
Posted On: 04/04/2019 6:06:09 PM
Re: Evil Rabbit #1754
Here’s what I gathered from the video:
1. The CYDY videos are getting better. I don’t like the “reporter” they use, as she seems unpolished and unrehearsed, but RP has been a nice edition as he is very professional and does a great job explaining the cancer indications for leronlimab.
2. NP makes it seem that a licensing deal for HIV isn’t far off. Although in the video yesterday he said that it could be as late as later this year. But he had mentioned the manufacturing deal over the past month or two and the announcement was made this week, so maybe we’ll see something during spring or early summer.
3. Leronlimab for cancer will change the path of CYDY. When I invested back in 2015, HIV was the main focus with a few other, smaller indications. Now with the addition of RP, the prostate test and the recent CCR5 discoveries, leronlimab has many high revenue producing indications if similar results are seen in humans as they were in the mice models.
4. As others and myself have stated, the HIV licensing and/or prostate test licensing will help CYDY increase in value but more importantly finance loernlimab trials in cancer.
1. The CYDY videos are getting better. I don’t like the “reporter” they use, as she seems unpolished and unrehearsed, but RP has been a nice edition as he is very professional and does a great job explaining the cancer indications for leronlimab.
2. NP makes it seem that a licensing deal for HIV isn’t far off. Although in the video yesterday he said that it could be as late as later this year. But he had mentioned the manufacturing deal over the past month or two and the announcement was made this week, so maybe we’ll see something during spring or early summer.
3. Leronlimab for cancer will change the path of CYDY. When I invested back in 2015, HIV was the main focus with a few other, smaller indications. Now with the addition of RP, the prostate test and the recent CCR5 discoveries, leronlimab has many high revenue producing indications if similar results are seen in humans as they were in the mice models.
4. As others and myself have stated, the HIV licensing and/or prostate test licensing will help CYDY increase in value but more importantly finance loernlimab trials in cancer.
(0)
(0)